AbClon Inc. (KOSDAQ:174900)
30,900
-3,100 (-9.12%)
Aug 12, 2026, 3:30 PM KST
AbClon Revenue
AbClon had revenue of 434.20M KRW in the quarter ending March 31, 2026, with 5.22% growth. This brings the company's revenue in the last twelve months to 4.74B, up 104.55% year-over-year. In the year 2025, AbClon had annual revenue of 4.71B with 101.47% growth.
Revenue (ttm)
4.74B
Revenue Growth
+104.55%
P/S Ratio
143.25
Revenue / Employee
n/a
Employees
n/a
Market Cap
678.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.71B | 2.37B | 101.47% |
| Dec 31, 2024 | 2.34B | -537.21M | -18.67% |
| Dec 31, 2023 | 2.88B | -527.18M | -15.49% |
| Dec 31, 2022 | 3.40B | 386.15M | 12.79% |
| Dec 31, 2021 | 3.02B | 246.87M | 8.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Chabiotech | 1.29T |
| Medy-Tox | 244.02B |
| MEDIPOST | 73.90B |
| Onconic Therapeutics | 67.20B |
| Pharmicell | 23.94B |
| GI Innovation | 5.63B |
| Genomictree | 3.83B |